Want to see FLNA full AI Analyst Report?

Filana Therapeutics (FLNA) Price & Analysis

3,917 Followers

FLNA Stock Chart & Stats

$0.93

$0.02(2.09%)

At close: Jul 27 4:00 PM EDT

$0.93

$0.02(2.09%)

Day’s Range― - ―

52-Week Range$0.67 - $4.98

Previous CloseN/A

Volume114.73K

Average Volume (3M)3.96M

Market Cap

$39.40M

Enterprise Value-$25.19M

Total Cash (Recent Filing)$82.68M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.20

Next Earnings

Nov 11, 2026

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend Yield207.51%

Share Statistics

EPS (TTM)-0.66

Shares Outstanding48,307,896

10 Day Avg. Volume1,408,336

30 Day Avg. Volume3,958,300

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.33

Price to Sales (P/S)0.00

P/FCF Ratio-3.02

Enterprise Value/Market Cap-0.64

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit37.77

Enterprise Value/Ebitda0.79

Forecast

1Y Price Target

$6.50

Price Target Upside598.92% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.95

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Very Low LeverageNear-zero debt reduces mandatory financing costs and limits the risk that creditors constrain strategic decisions. This gives Filana greater flexibility to direct available capital toward clinical development, although the benefit is tempered by its continuing need to fund operations.

Clinical Development ReactivatedRemoval of the full clinical hold restores the company’s ability to generate prospective human data for simufilam. A Phase 2a study can clarify safety, pharmacokinetics, and efficacy signals, creating a more durable basis for future development, partnering, or financing.

Targeted Rare-disease OpportunityFocusing on refractory TSC-related epilepsy addresses a clearly described unmet need and gives the program a defined patient population. If clinical data support the proposed mechanism, this specialization could help Filana establish relevance in a rare-disease market with limited treatment success.

Bears Say

No Revenue And Recurring LossesThe absence of revenue leaves Filana dependent on clinical progress and future commercialization or partnering to create economic value. Persistent losses, including renewed deterioration in 2025, reduce profitability visibility and make the business highly sensitive to development spending and execution.

Persistent Cash BurnOngoing negative operating and free cash flow means the company cannot currently fund its development program from internal operations. Even with improved burn versus 2024, continued funding needs can require additional capital and may constrain the pace or scope of clinical investment.

Shrinking Financial BaseThe sustained contraction in equity and total assets reflects cumulative losses and capital consumption, weakening financial flexibility over time. A smaller balance-sheet base leaves less capacity to absorb setbacks or support extended trials without raising additional funds or changing spending plans.

Filana Therapeutics News

Filana can proceed with study as hold lifted, says Lucid Capital

Lucid Capital analyst Elemer Piros reiterates a Buy rating on Filana Therapeutics (FLNA) with an $8 price target...

18d ago

FLNA

Filana Therapeutics announces U.S. FDA lifted clinical hold on simufilam

Filana Therapeutics (FLNA) announced that the U.S. Food and Drug Administration, FDA, has lifted the clinical hold on...

18d ago

FLNA

Hewlett Packard, Everpure, Filana, Ciena & Marriott Insider Shake‑Up

Insiders have been trading these 5 stocks: (($HPE)), (($P)), (($FLNA)), (($CIEN)) and (($MAR)). Here is a breakdown of...

7d ago

HPE

Filana Therapeutics advances simufilam in TSC epilepsy trial

Filana Therapeutics ( ($FLNA) ) just unveiled an update. On September 22, 2026, Filana Therapeutics announced that the...

18d ago

FLNA

Filana Therapeutics Receives Nasdaq Minimum Bid Price Notice

Filana Therapeutics ( ($FLNA) ) has shared an update. On September 17, 2026, Filana Therapeutics, Inc. disclosed that...

21d ago

FLNA

Cassava Sciences Securities Litigation Ruling: Court Denies Ugarte Dismissal Motions Without Prejudice While Awaiting Fifth Circuit Ruling

A federal judge in Texas has issued a procedural order in the securities litigation involving Filana Therapeutics, Inc.,...

2M ago

FLNA

FLNA Earnings this Week: How Will it Perform?

Filana Therapeutics, Inc. (FLNA) is scheduled to report 2nd quarter earnings on 08/05/2026, before the market opens. Regarding...

2M ago

FLNA

Jason McCarthy Reiterates Buy on Filana, Maintains Unchanged $5 Price Target Amid Advancing Simufilam TSC Epilepsy Strategy

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Filana Therapeutics, with...

2M ago

FLNA

Filana Therapeutics Shareholders Back Board, Compensation Plans

Filana Therapeutics ( ($FLNA) ) has issued an announcement. Filana Therapeutics held its 2026 Annual Meeting of Stockholders...

4M ago

FLNA

BridgeBio, Dave, Marvell, Filana, GE Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($BBIO) ), ( ($DAVE) ), ( ($MRVL) ), ( ($FLNA)...

4M ago

BBIO

Filana Therapeutics resumed with Buy at Maxim on rebranding, strategic pivot

As previously reported, Maxim resumed coverage of Filana Therapeutics (FLNA) with a Buy rating and $5 price target...

5M ago

FLNA

Filana Therapeutics resumed with a Buy at Maxim

Maxim resumed coverage of Filana Therapeutics (FLNA) with a Buy rating and $5 price target Published first on...

5M ago

FLNA

Filana Therapeutics publishes simufilam preclinical data

Filana Therapeutics (FLNA) announced publication in Epilepsia of preclinical data showing that simufilam attenuated seizure progression in a...

6M ago

FLNA

Filana Therapeutics management to meet with Maxim

Meeting to be held on March 24-25 hosted by Maxim. Published first on TheFly – the ultimate source...

7M ago

FLNA

FLNA FAQ

What was Filana Therapeutics’s price range in the past 12 months?

Filana Therapeutics lowest stock price was $0.67 and its highest was $4.98 in the past 12 months.

What is Filana Therapeutics’s market cap?

Filana Therapeutics’s market cap is $39.40M.

When is Filana Therapeutics’s upcoming earnings report date?

Filana Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 32 days.

How were Filana Therapeutics’s earnings last quarter?

Filana Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.225 by $0.045.

Is Filana Therapeutics overvalued?

According to Wall Street analysts Filana Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Filana Therapeutics pay dividends?

Filana Therapeutics pays a Notavailable dividend of $5.25 which represents an annual dividend yield of 207.51%. See more information on Filana Therapeutics dividends here

What is Filana Therapeutics’s EPS estimate?

Filana Therapeutics’s EPS estimate is -0.25.

How many shares outstanding does Filana Therapeutics have?

Filana Therapeutics has 48,307,896 shares outstanding.

What happened to Filana Therapeutics’s price movement after its last earnings report?

Filana Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.225. Following the earnings report the stock price went down -3.715%.

Which hedge fund is a major shareholder of Filana Therapeutics?

Currently, no hedge funds are holding shares in FLNA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Filana Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-58.78%

Trailing 12-Months

Asset Growth

-23.25%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Filana Therapeutics

Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.

Filana Therapeutics (FLNA) Earnings & Revenues

Historic Earnings Reports

FLNA Stock 12 Month Forecast

Average Price Target

$6.50

▲(598.92% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.965,1.5061538461538462,2.0473076923076925,2.5884615384615386,3.1296153846153847,3.670769230769231,4.211923076923077,4.753076923076923,5.2942307692307695,5.835384615384616,6.376538461538462,6.917692307692308,7.458846153846155,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.965,1.3907692307692308,1.8165384615384617,2.2423076923076923,2.668076923076923,3.0938461538461537,3.519615384615385,3.9453846153846155,4.371153846153846,4.796923076923077,5.2226923076923075,5.648461538461539,6.07423076923077,{"y":6.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.965,1.2753846153846153,1.5857692307692308,1.896153846153846,2.2065384615384613,2.5169230769230766,2.8273076923076923,3.1376923076923076,3.448076923076923,3.758461538461538,4.068846153846153,4.3792307692307695,4.689615384615385,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.857,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.965,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >